1. Gresele P, Morni S, Falcinelli E. Antiplatelet therapy: phosphodiesterase inhibitors. Brazilian Journal of Clinical Pharmacology. 2011;72(4):634-46.
2. Chen W, Chen Y, et al. Cilostazol promotes vascular smooth muscles cell differentiation through the cAMP response element-binding protein-dependent pathway. Arteriosclerosis, Thrombosis, and Vascular Biology. 2011;31(9):2106-13.
3. Kherallah RY, Khawaja M, et al. Cilostazol: a Review of Basic Mechanisms and Clinical Uses. Cardiovasc Drugs Ther. 2022 Aug;36(4):777-792. doi: 10.1007/s10557-021-07187-x. Epub 2021 Apr 16. PMID: 33860901.
4. Castellsague J, Perez-Gutthann S, et al. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiology and Drug Safety. 2017;26(6):615-24.
5. Gerhard-Herman M, Gornik H, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;135(12):e686-725.
6. Xie W, Zheng F, et al. Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis. Journal of AMerican Heart Association. 2015;4(8):e002259.
7. Tan L, Margaret B, et al. Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis. Journal of Stroke and Cerebrovascular Disease. 2015;24(5):930-8.
8. Shi L, Pu J, et al. The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. BMC Neurol. 2014;14(14):251.
9. Kwok C, Shoamanesh A, et al. Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials. Stroke. 2015;46(4):1014-23.
10. Malloy R, Kanaan A, et al. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. Clinical Therapeutics. 2013;35(10):1490-500.
11. Bangalore S, Singh A, et al. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart. 2015;2014(1):e000068
12. Xue Y, Feng Z-w,et al. The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. Acta Pharmacologica Sinica. 2018;39(2018):205-12
13. Iida O, Yokoi H, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation. 2013;127(23):2307-15.
14. Iida O, Nanto S, et al. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. Journal of Vascular Surgery. 2008;48(1):144-9.
15. Kwon SU, Hong K-S, et al. Efficacy and Safety of Combination Antiplatelet Therapies in Patients With Symptomatic Intracranial Atherosclerotic Stenosis. Stroke. 2011;42(10):2883-90.
16. Lee S, Choi S, et al. Impact of chronotropic effect of cilostazol after acute myocardial infarction: insights from change in left ventricular volume and function. Circulation. 2007;71(1):106-11.
17. de Donato G, Setacci F, et al. The use of cilostazol in patients with peripheral arterial disease: results of a national physician survey. Journal of Cardiovascular Surgery (Torino). 2016;57(3):457-65.
18. Keputusan Menteri Kesehatan Tentang Perubahan Atas Keputusan Menteri Kesehatan Nomor HK.01.07/MENKES/659/2017 Tentang Formularium Nasional. Jakarta 2018.
19. McHutchison C, Blair GW, et al. Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis. Stroke. 2020 Aug;51(8):2374-2385. doi: 10.1161/STROKEAHA.120.029454. Epub 2020 Jul 10. PMID: 32646330; PMCID: PMC7382534.